Scarica l'app Stockscreener
3.35
8.47%
-0.31
Dopo l'orario di chiusura:
3.49
0.14
+4.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Precedente Chiudi:
$3.66
Aprire:
$3.6
Volume 24 ore:
685.75K
Relative Volume:
1.01
Capitalizzazione di mercato:
$207.76M
Reddito:
-
Utile/perdita netta:
$-73.79M
Rapporto P/E:
-1.8207
EPS:
-1.84
Flusso di cassa netto:
$-77.44M
1 W Prestazione:
-12.53%
1M Prestazione:
+63.41%
6M Prestazione:
+258.71%
1 anno Prestazione:
+1.52%
Intervallo 1D:
$3.34
$3.82
Intervallo di 1 settimana:
$3.1501
$3.8851
Portata 52W:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Nome
Pyxis Oncology Inc
Settore
Industria
Telefono
(617) 221-9059
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta PYXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.35 | 200.32M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2024-11-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-08-08 | Iniziato | Stifel | Buy |
| 2024-05-07 | Ripresa | Jefferies | Buy |
| 2024-02-09 | Iniziato | BTIG Research | Buy |
| 2024-01-23 | Iniziato | Leerink Partners | Outperform |
| 2023-09-05 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-02 | Iniziato | BofA Securities | Neutral |
| 2021-11-02 | Iniziato | Credit Suisse | Outperform |
| 2021-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Will Pyxis Oncology Inc. stock deliver better than expected guidance2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Smart tools for monitoring Pyxis Oncology Inc.’s price actionSwing Trade & AI Based Buy/Sell Signal Reports - newser.com
Pyxis Oncology (NASDAQ:PYXS) Upgraded at Zacks Research - Defense World
Will Pyxis Oncology Inc. stock continue upward momentumEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
How risky is Pyxis Oncology Inc. stock nowJuly 2025 Decliners & Breakout Confirmation Alerts - newser.com
Why Pyxis Oncology Inc. stock is a value investor pickIPO Watch & Weekly High Return Opportunities - newser.com
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics - Yahoo Finance
Strategies to average down on Pyxis Oncology Inc.Chart Signals & Reliable Price Action Trade Plans - newser.com
What makes Pyxis Oncology Inc. stock attractive to growth fundsQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery - Yahoo Finance
Pyxis Oncology to Present Translational Data and Key - GlobeNewswire
ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025 - Stock Titan
Can Pyxis Oncology Inc. stock beat analyst upgradesTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Full technical analysis of Pyxis Oncology Inc. stockJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Developing predictive dashboards with Pyxis Oncology Inc. data2025 Analyst Calls & Technical Confirmation Trade Alerts - newser.com
Pyxis Oncology Gains 70%, Insider Trades Reap Benefit - 富途牛牛
Pyxis Oncology (NASDAQ:PYXS) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Will Pyxis Oncology Inc. see short term momentumVolume Spike & Pattern Based Trade Signal System - newser.com
Is Pyxis Oncology Inc. stock undervalued vs historical averages2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Is Pyxis Oncology Inc. stock a top pick in earnings seasonRate Cut & AI Enhanced Trading Signals - newser.com
Real time pattern detection on Pyxis Oncology Inc. stockMarket Growth Report & Community Consensus Picks - newser.com
Pyxis Oncology, Inc. Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets, Effective October 9, 2025 - MarketScreener
Pyxis Oncology appoints Alex Kane as SVP of investor relations By Investing.com - Investing.com Australia
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Quiver Quantitative
Pyxis Oncology appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - MarketScreener
Volume spikes in Pyxis Oncology Inc. stock – what they mean2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Pyxis Oncology Inc.’s future2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
How institutional ownership impacts Pyxis Oncology Inc. stockMarket Sentiment Review & Daily Momentum Trading Reports - newser.com
What to do if you’re stuck in Pyxis Oncology Inc.Trade Risk Summary & Free High Return Stock Watch Alerts - newser.com
Pyxis Oncology Inc Azioni (PYXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):